{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T22:36:51Z","timestamp":1777934211472,"version":"3.51.4"},"reference-count":19,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2013,5,14]],"date-time":"2013-05-14T00:00:00Z","timestamp":1368489600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2014,2]]},"abstract":"<jats:sec>\n                    <jats:title>Background and purpose<\/jats:title>\n                    <jats:p>Dexrazoxane is used clinically to prevent anthracycline-associated cardiotoxicity. Hydrolysis of dexrazoxane prior to reaching the cardiac membranes severely hampers its mode of action; therefore, degradation during the preparation and administration of intravenous dexrazoxane admixtures demands special attention. Moreover, the ongoing national shortage of one dexrazoxane formulation in the United States has forced pharmacies to dispense other commercially available dexrazoxane products. However, the manufacturers\u2019 limited stability data restrict the flexibility of dexrazoxane usage in clinical practice. The aims of this study are to determine the physical and chemical stability of reconstituted and diluted solutions of two commercially available dexrazoxane formulations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The stability of two dexrazoxane products, brand and generic name, in reconstituted and intravenous solutions stored at room temperature without light protection in polyvinyl chloride bags was determined. The concentrations of dexrazoxane were measured at predetermined time points up to 24\u2009h using a validated reversed phase high-performance liquid chromatography with ultraviolet detection assay.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Brand (B-) and generic (G-) dexrazoxane products, reconstituted in either sterile water or 0.167\u2009M sodium lactate (final concentration of 10\u2009mg\/mL), were found stable for at least to 8 h. Infusion solutions of B-dexrazoxane, prepared according to each manufacturer\u2019s directions, were stable for at least 24 h and 8\u2009h at 1\u2009mg\/mL and 3\u2009mg\/mL, respectively. Infusion solutions of G-dexrazoxane, prepared in either 5% dextrose or 0.9% sodium chloride following the manufacturer\u2019s guidelines, were also stable for at least 24 h and 8\u2009h at 1\u2009mg\/mL and 3\u2009mg\/mL, respectively. All tested solutions were found physically stable up to 24 h at room temperature.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The stability of dexrazoxane infusion solutions reported herein permits advance preparation of dexrazoxane intravenous admixtures, facilitating pharmacy workflow and clinical operations. However, due to the potential risks of fluid overload when these intravenous solutions are administered to patients, caution is advised to ensure patient safety.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/1078155213480070","type":"journal-article","created":{"date-parts":[[2013,5,15]],"date-time":"2013-05-15T20:49:05Z","timestamp":1368650945000},"page":"58-64","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":7,"title":["Physical and chemical stability of reconstituted and diluted dexrazoxane infusion solutions"],"prefix":"10.1177","volume":"20","author":[{"given":"Yan-Ping","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Pharmacy Research, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan L","family":"Myers","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Research, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Van A","family":"Trinh","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Clinical Programs, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jitesh D","family":"Kawedia","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Research, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark A","family":"Kramer","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Research, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert S","family":"Benjamin","sequence":"additional","affiliation":[{"name":"Department of Sarcoma Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hai T","family":"Tran","sequence":"additional","affiliation":[{"name":"Departments of Thoracic, Head and Neck Medical Oncology and Pharmacy Research, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2013,5,14]]},"reference":[{"key":"bibr1-1078155213480070","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199856030-00009"},{"key":"bibr2-1078155213480070","doi-asserted-by":"publisher","DOI":"10.1016\/0305-7372(91)90002-H"},{"key":"bibr3-1078155213480070","unstructured":"Zinecard (dexrazoxane for injection) package insert\n                      . New York, NY: Pfizer, 2012."},{"key":"bibr4-1078155213480070","doi-asserted-by":"publisher","DOI":"10.3109\/08880018.2010.503335"},{"key":"bibr5-1078155213480070","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.2.362"},{"key":"bibr6-1078155213480070","unstructured":"ASHP. Drug shortages, http:\/\/www.ashp.org\/DrugShortages\/ (2012, accessed 14 November 2012)."},{"key":"bibr7-1078155213480070","unstructured":"Mylan.\n                      Dexrazoxane hydrochloride package insert\n                      . Rockford, IL: Mylan, 2012."},{"key":"bibr8-1078155213480070","first-page":"166","volume":"47","author":"Beijnen JH","year":"1993","journal-title":"J Parenter Sci Technol"},{"key":"bibr9-1078155213480070","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp070293"},{"key":"bibr10-1078155213480070","unstructured":"Food and Drug Administration (FDA). Guideline for submitting supporting documentation in drug applications for the manufacture of drug substances, www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/ucm070632.pdf (1987, accessed 23 January 2013)."},{"key":"bibr11-1078155213480070","doi-asserted-by":"publisher","DOI":"10.1177\/1078155207080118"},{"key":"bibr12-1078155213480070","first-page":"2359","volume":"50","author":"Trissel LA","year":"1993","journal-title":"Am J Hosp Pharm"},{"key":"bibr13-1078155213480070","doi-asserted-by":"publisher","DOI":"10.1331\/108658002762063718"},{"key":"bibr14-1078155213480070","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1E408"},{"key":"bibr15-1078155213480070","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1G715"},{"key":"bibr16-1078155213480070","doi-asserted-by":"publisher","DOI":"10.1016\/S1086-5802(15)30399-5"},{"key":"bibr17-1078155213480070","first-page":"1716","volume":"49","author":"Trissel LA","year":"1992","journal-title":"Am J Hosp Pharm"},{"key":"bibr18-1078155213480070","unstructured":"U.S. Pharmacopeial Convention. The United States Pharmacopeia and The National Formulary (USP-NF), www.usp.org\/usp-nf (accessed 24 January 2013)."},{"key":"bibr19-1078155213480070","first-page":"55","volume":"13","author":"Kaiser J","year":"2007","journal-title":"EJHP Sci"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155213480070","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1078155213480070","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155213480070","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:14:57Z","timestamp":1777688097000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1078155213480070"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5,14]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["10.1177\/1078155213480070"],"URL":"https:\/\/doi.org\/10.1177\/1078155213480070","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,5,14]]}}}